The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Estimated impact of novel immune checkpoint inhibitors on reducing cancer mortality in patients with locally advanced or metastatic urothelial carcinoma in Russia.
 
Boris Alekseev
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Merck; MSD; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Merck; MSD; Pfizer; Roche
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; Merck; MSD; Pfizer; Roche
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; ICON Clinical Research; Janssen; Merck; MSD; Pfizer; Roche
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Nikolay Avxentyev
Stock and Other Ownership Interests - BMS GmbH & Co. KG (I); Merck Serono (I); Pfizer (I)
Honoraria - JJ Innovative Medicine; Merck Serono; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - Merck Serono; Novartis; Pfizer; Roche
Research Funding - Astellas Pharma (Inst); JJ Innovative Medicine (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst)
 
Yuliya Makarova
No Relationships to Disclose
 
Irina Andreiashkina
Honoraria - Merck; Novartis; Roche